Real world safety of CT-P10 (anti-CD 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases

Real world safety of CT-P10 (anti-CD 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases

Abstract Background Rituximab (RTX), anti-CD 20 monoclonal antibodies, has been approved for many rheumatic and autoimmune diseases, the use of RTX is still limited due to financial constrain. Biosimilar RTX may increase access by offering patients a more affordable option, lead to improved patient...

Full description

Bibliographic Details
Main Authors: Wanruchada Katchamart, Pintip Ngamjanyaporn, Annop Orawongpaisarn, Thossapoom Phubangkertphon, Sasimon Borrirukwisitsak, Nichapa Dechapaphapitak
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Rheumatology
Subjects:
Rituximab
CT-P10
Biosimilar anti-CD 20 antibodies
Adverse event
Infusion reaction
Online Access:https://doi.org/10.1186/s41927-022-00306-7

Internet

https://doi.org/10.1186/s41927-022-00306-7

Similar Items